Editorial: Advance in B-cell therapies for the treatment of rheumatic and musculoskeletal diseases.
作者信息
Md Yusof Md Yuzaiful, Alivernini Stefano, Chatzidionysiou Katerina
机构信息
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom.
National Institute for Health and Care Research (NIHR) Leeds Biomedical Research Centre, Leeds Teaching Hospitals National Health Service (NHS) Trust, Leeds, United Kingdom.
出版信息
Front Med (Lausanne). 2022 Sep 21;9:1020859. doi: 10.3389/fmed.2022.1020859. eCollection 2022.
Abstract
摘要
相似文献
1
Editorial: Advance in B-cell therapies for the treatment of rheumatic and musculoskeletal diseases.社论：用于治疗风湿性和肌肉骨骼疾病的B细胞疗法进展
Front Med (Lausanne). 2022 Sep 21;9:1020859. doi: 10.3389/fmed.2022.1020859. eCollection 2022.
2
[Lymphoma in rheumatic diseases].[风湿性疾病中的淋巴瘤]
Z Rheumatol. 2017 Oct;76(Suppl 2):46-56. doi: 10.1007/s00393-017-0383-4.
3
A Summary on the Genetics of Systemic Lupus Erythematosus, Rheumatoid Arthritis, Systemic Sclerosis, and Sjögren's Syndrome.系统性红斑狼疮、类风湿关节炎、系统性硬化症及干燥综合征的遗传学综述
Clin Rev Allergy Immunol. 2023 Jun;64(3):392-411. doi: 10.1007/s12016-022-08951-z. Epub 2022 Jun 24.
4
[Recommendations of diagnosis and treatment of primary Sjögren's syndrome in China].《中国原发性干燥综合征诊断和治疗专家共识》
Zhonghua Nei Ke Za Zhi. 2020 Apr 1;59(4):269-276. doi: 10.3760/cma.j.cn112138-20200113-00021.
5
Motor neuron disease in a patient with overlap syndrome (rheumatoid arthritis; systemic lupus erythematosus, Sjogren's syndrome).重叠综合征（类风湿关节炎；系统性红斑狼疮、干燥综合征）患者的运动神经元病。
Rheumatol Int. 2023 Feb;43(2):367-372. doi: 10.1007/s00296-022-05207-z. Epub 2022 Sep 18.
6
Inositol 1,4,5-trisphosphate receptors are autoantibody target antigens in patients with Sjögren's syndrome and other systemic rheumatic diseases.在干燥综合征和其他系统性风湿性疾病患者中，肌醇1,4,5-三磷酸受体是自身抗体的靶抗原。
Mod Rheumatol. 2007;17(2):137-43. doi: 10.1007/s10165-006-0555-6. Epub 2007 Apr 20.
7
Primary Sjögren's syndrome.原发性干燥综合征
Lupus. 2018 Oct;27(1_suppl):32-35. doi: 10.1177/0961203318801673.
8
Biologics in the treatment of Sjogren's syndrome, systemic lupus erythematosus, and lupus nephritis.生物制剂治疗干燥综合征、系统性红斑狼疮和狼疮性肾炎。
Curr Opin Rheumatol. 2020 Nov;32(6):609-616. doi: 10.1097/BOR.0000000000000754.
9
Serum 14-3-3η protein is associated with clinical and serologic features of Sjögren's syndrome in patients with systemic lupus erythematosus: a cross-sectional analysis.血清14-3-3η蛋白与系统性红斑狼疮患者干燥综合征的临床和血清学特征相关：一项横断面分析。
Clin Rheumatol. 2020 Sep;39(9):2603-2610. doi: 10.1007/s10067-020-05033-3. Epub 2020 Mar 23.
10
Profiles of antinuclear antibodies in systemic rheumatic diseases.系统性风湿性疾病中的抗核抗体谱
Ann Intern Med. 1975 Oct;83(4):464-9. doi: 10.7326/0003-4819-83-4-464.
本文引用的文献
1
Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial.超低剂量利妥昔单抗持续治疗类风湿关节炎（REDO研究）：一项随机对照非劣效性试验
Lancet Rheumatol. 2019 Nov;1(3):e145-e153. doi: 10.1016/S2665-9913(19)30066-9. Epub 2019 Oct 23.
2
Predicting Sustained Clinical Response to Rituximab in Moderate to Severe Systemic Manifestations of Primary Sjögren Syndrome.预测利妥昔单抗治疗原发性干燥综合征中重度全身表现的持续临床反应
ACR Open Rheumatol. 2022 Aug;4(8):689-699. doi: 10.1002/acr2.11466. Epub 2022 Jun 5.
3
Factors Determining Retreatment Time Interval of Rituximab in Korean Patients With Rheumatoid Arthritis.韩国类风湿关节炎患者中决定利妥昔单抗再治疗时间间隔的因素
Front Med (Lausanne). 2021 Oct 28;8:765535. doi: 10.3389/fmed.2021.765535. eCollection 2021.
4
Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus : A Randomized Controlled Trial.贝利尤单抗治疗系统性红斑狼疮的有效性：一项随机对照试验。
Ann Intern Med. 2021 Dec;174(12):1647-1657. doi: 10.7326/M21-2078. Epub 2021 Oct 26.
5
Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus.III/IV 期、随机、52 周、评估贝利尤单抗在黑种人系统性红斑狼疮患者中的疗效和安全性的研究。
Arthritis Rheumatol. 2022 Jan;74(1):112-123. doi: 10.1002/art.41900. Epub 2021 Dec 9.
6
JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis.JAK抑制剂与类风湿关节炎中B细胞免疫反应的调节
Front Med (Lausanne). 2021 Feb 5;7:607725. doi: 10.3389/fmed.2020.607725. eCollection 2020.
7
Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies.利妥昔单抗后接贝利尤单抗可控制对多种联合疗法难治的系统性红斑狼疮中的重症狼疮性肾炎和大疱性类天疱疮。
Front Med (Lausanne). 2020 Oct 28;7:553075. doi: 10.3389/fmed.2020.553075. eCollection 2020.
8
Comparison of Rituximab Originator With CT-P10 Biosimilar in Patients With Primary Sjögren's Syndrome: A Retrospective Analysis in a Real-Life Setting.利妥昔单抗原研药与CT-P10生物类似药治疗原发性干燥综合征患者的比较：真实临床环境中的回顾性分析
Front Med (Lausanne). 2020 Sep 8;7:534. doi: 10.3389/fmed.2020.00534. eCollection 2020.
9
Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than Belimumab.系统性红斑狼疮中的生物测序：在对利妥昔单抗继发无反应后，换用人源化抗CD20药物比贝利尤单抗更有效。
Front Med (Lausanne). 2020 Aug 27;7:498. doi: 10.3389/fmed.2020.00498. eCollection 2020.
10
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.两年随机对照试验研究贝利尤单抗治疗狼疮肾炎。
N Engl J Med. 2020 Sep 17;383(12):1117-1128. doi: 10.1056/NEJMoa2001180.
Zotero 插件